Geode Capital Management LLC Purchases 48,018 Shares of Illumina, Inc. (NASDAQ:ILMN)

Geode Capital Management LLC boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.8% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,727,827 shares of the life sciences company’s stock after acquiring an additional 48,018 shares during the quarter. Geode Capital Management LLC owned 1.72% of Illumina worth $354,933,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC grew its position in shares of Illumina by 23.1% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 9,755 shares of the life sciences company’s stock valued at $1,018,000 after acquiring an additional 1,831 shares during the period. Great Valley Advisor Group Inc. bought a new stake in Illumina during the second quarter valued at about $201,000. ORG Partners LLC purchased a new stake in Illumina in the second quarter worth about $79,000. Blue Trust Inc. raised its stake in shares of Illumina by 2,203.6% in the second quarter. Blue Trust Inc. now owns 2,534 shares of the life sciences company’s stock worth $264,000 after buying an additional 2,424 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its position in shares of Illumina by 3.6% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 399,966 shares of the life sciences company’s stock valued at $41,748,000 after buying an additional 13,725 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on ILMN. Stephens raised their target price on shares of Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. UBS Group upped their target price on shares of Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Daiwa Capital Markets upgraded Illumina from a “neutral” rating to a “buy” rating and increased their price target for the stock from $120.00 to $154.00 in a research note on Friday, August 16th. Hsbc Global Res upgraded Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective on the stock in a research report on Thursday, October 17th. Finally, StockNews.com assumed coverage on Illumina in a research report on Thursday, August 29th. They set a “buy” rating for the company. Nine analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Illumina currently has an average rating of “Moderate Buy” and a consensus price target of $165.40.

Illumina Stock Down 1.7 %

Shares of NASDAQ:ILMN opened at $143.87 on Friday. The company has a market cap of $22.82 billion, a price-to-earnings ratio of -14.44 and a beta of 1.11. Illumina, Inc. has a 12 month low of $100.08 and a 12 month high of $156.66. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. The company has a 50-day moving average price of $144.27 and a 200 day moving average price of $128.28.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.26. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same period last year, the company earned $0.33 EPS. As a group, equities research analysts predict that Illumina, Inc. will post 4.11 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.